Donate For Public and Patients Store Search

F013 - Dermatologists to the Rescue - Great Cases from Safety-net Hospitals

Friday, March 1; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss individual patient cases with advanced disease and/or limited resources that pose diagnostic, treatment, and management challenges
  • Describe the diagnostic, treatment, and management “pearls” that can advance dermatologic care of these challenging patients

Description

The purpose is to discuss dermatologic cases seen in safety-net hospitals with take-away lessons related to diagnosis, treatment, and management. Patients in this setting often have advanced skin disease, and limited health care resources. After a brief introductory talk about safety-net hospitals and their patient populations, speakers will present individual patient examples and provide diagnostic, treatment, and management tips that are applicable to a wide audience, many of whom are confronted with patients with similar cases. Speakers will focus on separate disease categories including skin neoplasms, infections, and inflammatory and autoimmune skin diseases. The intended audience is practicing medical dermatologists.

Disclosures

  • Albrecht, Joerg, MD: AbbVie – I(Fees); AiCuris GmbH & Co. KG – I(Fees);
  • Amerson, Erin H., MD: no financial relationships exist with commercial interests.
  • Chong, Benjamin F., MD, MSc: Biogen – I(Grants/Research Funding); Celgene Corporation – A(H); Daavlin Company – I(Grants/Research Funding); ICON Medical Imaging – C(H); Pfizer Inc. – I(Grants/Research Funding); Viela Bio – C(H);
  • Colven, Roy Mitchell, MD: no financial relationships exist with commercial interests.
  • Hsu, Sylvia, MD: AbbVie – A(H); Amgen – A(H); Celgene – I(Fees); Centocor Ortho Biotech Inc. – I(Fees); Corrona, Inc. – I(Fees); Dr. Reddy – A(H); Eli Lilly and Company – A(H); Genentech, Inc. – A(H); Janssen Pharmaceuticals, Inc – A(H); Novartis – A(H); Promius Pharma, LLC – A(H); Ranbaxy Laboratories Limited – A(H); Sanofi/Regeneron – A(H); Valeant Pharmaceuticals North America LLC – A(H);
  • Maurer, Toby A., MD: no financial relationships exist with commercial interests.
Event Details
  • Date
    Friday, March 1
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 101
  • CME Credits
    2.00
  • Type
    New
Directors/Co-Directors
  • Benjamin F. Chong, MD, MSc, FAAD - Handout
Speakers
  • Erin H. Amerson, MD, FAAD
  • Joerg Albrecht, MD, FAAD
  • Roy Mitchell Colven, MD, FAAD
  • Sylvia Hsu, MD, FAAD
  • Toby A. Maurer, MD, FAAD